OBJECTIVES: Parenteral nutrition (PN) is critical in neonatal and pediatric care for patients unable to tolerate enteral feeding. This study assessed the total costs of compounding PN therapy for neonates, infants and children. METHODS: Face-to-face and telephone interviews were conducted in 12 hospitals across four European countries (Belgium, France, Germany and UK) to collect information on resources utilized to compound PN, including nutrients, staff time, equipment cost and supplies. A bottom-up cost model was constructed to assess total costs of PN therapy by assigning monetary values to the resource utilization using published list prices and interview data. RESULTS: A total of 49 922 PN bags per year were used to treat 4295 neonatal and pediatric patients among these hospitals. The daily total costs of one compounded PN bag for neonates in the 12 hospitals across the four countries equalled h55.16 (Belgium h53.26, France h46.23, Germany h64.05, UK Ł37.43/h42.86). Overall, nutrients accounted for 25% of total costs, supplies 18%, wages 54% and equipment 3%. Average costs per bag for infants o2 year were h84.52 (h74.65 in Belgium, h83.84 in France, h92.70 in Germany and Ł52.63/h60.26 in the UK), and for children 2 --18 years h118.02 (h93.85 in Belgium, h121.35 in France, h124.54 in Germany and Ł69.49/h79.56 in the UK), of which 63% is attributable to nutrients and 28% to wages. CONCLUSION: The data indicated that PN costs differ among countries and a major proportion was due to staff time (Ł1 ¼ h1.144959).
INTRODUCTION
Parenteral nutrition (PN) for neonates and children is highly complex and differs from adults. Their energy expenditures are not only related to the maintenance of body tissue but also to additional needs for growth and development.
1,2 Special guidelines have been developed to address the needs of parenteral nourished neonates and children. 1 In general, two mechanisms to deliver PN are available: standard PN solutions, or individualized admixtures compounded in hospital or by external suppliers. Commercial standard solutions are mainly available for adults and children older than 2 years, except in France and UK, where commercial standard solutions for neonates are available. These standard bags are not fully ready-touse; electrolytes, vitamins, trace elements and fat emulsions are frequently added to the bag. In hospital, compounded admixtures are prepared as sterile solutions either in a hospital pharmacy under the responsibility of a hospital pharmacist or directly in the ward. Differences exist in the preparation and administration of pediatric PN in different European countries, which are mainly related to usual practices in the country. In France, the production process must comply with strict quality standards for infusions; 3 due to a statutory requirement preparations should be manufactured in the pharmacy in France. 4 In the UK, tailored PN preparations must be made under controlled pharmaceutical conditions and not at ward level. 5 In Germany and Belgium, PN can be compounded either in the ward or the pharmacy.
We conducted a systematic literature search to find comparable cost studies for pediatric PN. Two studies were found: Gamsjäger et al. 2 and Rey et al. 6 Both analyses were conducted only in one hospital and Gamsjäger only considered nutrient costs, and therefore additional research is needed (study details and results are mentioned in the discussion section).
Considering the limited cost data on pediatric PN, this study aimed to create a multi-country model able to assess the total costs per PN bag and per neonate, infant and child using formulations manufactured in hospital, either in a pharmacy or in the ward.
MATERIALS AND METHODS
A total of 12 face-to-face and telephone interviews with a team of healthcare professionals (physicians, pharmacists and nurses) in each of the recruited hospitals were conducted to collect resource use information on nutrients, staff time, equipment and supplies for the patient groups: neonates (pre-term and term with different weight groups); infants (o2 years excluding newborns); and children (between 2 and 18 years). In total there were 12 hospitals across four European countries recruited, at least 3 in every country (Belgium, France, Germany and UK). A cost model connecting the above mentioned resource use information per country with publicly listed national manufacturer prices without discounts and interview data was constructed to estimate the total costs for a PN bag and for a patient.
The following study design was applied:
(1) A systematic literature review was conducted using MEDLINE, EMBASE, HEED and SciSearch to find publications on the costs of compounded pediatric PN. (2) An interview guide/questionnaire was then developed. 
Organization of the hospital production
The data from the 12 questionnaires show that 49 922 pediatric PN bags were administered in the hospitals, of which 45 965 (92%) were compounded in the hospitals (93% in Belgium, 96% in Germany and the UK and 89% in France). France and the UK compound exclusively in the hospital pharmacy. In Germany, pharmacy compounding represented 40% of the total in-hospital production, the equivalent in Belgium being 80%. Hospital personnel involved in the compounding process receive training, and a bacteriology quality test is undertaken daily in the pharmacy and weekly in the ward.
Cost analysis
To compare costs of equivalent nutritional value, the study was performed for the most frequently compounded all-in-one formulation with carbohydrates, amino acids and fat emulsions in three compartments of one bag; electrolytes, vitamins and trace elements are also added to PN bags. Fat emulsions are either included or are administered separately.
Current list prices were used to estimate nutrient, supply and equipment costs on a country base. Wage costs were taken as the mean gross salary per country for each category of hospital personnel and were derived from official statistics for the countries in question (Belgian Federal Government, oral information 5 April 2011). 7 --13 Fixed and variable costs were taken into account to determine the cost of producing an in-hospital formulation. Variable costs depended on the type of formulation and included the costs of the raw materials/nutrients and supply items. Fixed costs included quality control, depreciation of equipment and facilities, and personnel costs. 14 Costs for the UK in British Pounds were converted to Euro, using the exchange rate Ł1 ¼ h1.144959.
Nutrient costs. The costs for the nutrients per bag/bottle were calculated by multiplying the unit price of the corresponding nutrients with the volume used per bag. Nutrients used were fat emulsions, glucose, amino acids, electrolytes, trace elements and vitamins. The nutrient prices represent the list price from official price lists in the countries in question. 15 --19 The bag size for each patient group was derived from the interviews and is based on hospital records. The average bottle/bag size for preterm neonates born p1000 g was 150 ml; for those born between 1001 --1500 g, 220 ml; for those born between 1501 --2500 g, 250 ml; and for those born above 2500 g, 250 ml. Infants and children needed on average 500 ml and 1000 ml PN per day, respectively.
Supply costs. Supplies included disposable materials (bags, bottles, needles, swabs, transfer systems, syringes, cannulas, catheters and labels), garments (sterile gloves, disposable headwear, masks and overshoes, and the clean room suit) and antiseptics. The costs of supply items was calculated per bag, and the prices used from official price lists and if not available from the interviews. 15, 19 Equipment costs. Depreciation was calculated linearly over a 5-year period for installation and devices (laminar flow hood/bench, compounder, infusion pump, isolator). Information about the price and yearly maintenance costs for the equipment was derived from the recruited sites, which took the information from hospital records.
The costs for the quality control per bag were calculated from the billing prices provided by the bacteriology laboratories. Data from the interviews showed that quality controls take place on average daily in the pharmacy and weekly in the ward. The basis for the calculation was the average number of bags used per day or week.
Personnel costs. Time spent by each category of personnel to produce the nutrient preparations (prescription, preparation for compounding, 
disconnection, stock management/requisition, quality control and training time) were recorded ( Table 2 ). The PN activities of physicians, pharmacist and nurse were systematically timed by the respondents. These timings were combined with the average wages per country of the personnel involved in the activities. The corresponding salary information was obtained via official statistical sources (Belgian Federal Government, oral information 5 April 2011).
--13
Sensitivity analyses on variation of staff time and discounts on list prices of nutrients
One-way sensitivity analyses were performed to vary uncertain parameters to see which variables are influential. The sensitivity analyses were calculated for: (1) the discounts off the list price of nutrients; (2) the variation of staff wage costs. The ranges of the variations were derived from the interviews.
RESULTS
The number of days of PN for neonates depended on their weight group. Generally, the treatment course of PN becomes shorter with increasing birth weight. The average PN days were calculated per country and ranged for preterm neonates 1000 g between 29 in France and 25 in the UK. Neonates with a birth weight 42500 g received PN for approximately 1 week. Neonates (aggregated over all weight groups) had an average treatment duration between 11 and 13 days. Infants o2 years received treatment between 4 and 9 days of PN, while children between 2 and 18 years received treatment at 9 or 10 days.
Costs per bag of PN The in-hospital costs of providing patients with PN are summarized in Table 3 . Ward compounding is more time intensive than pharmacy compounding, due to a mainly manual compounding process (66 vs 93.83 min --see Table 2 ). Total costs include costs of nutrients, supplies, installation and devices, and wage costs. The daily total average cost of one PN bag compounded in-hospital across all weight groups and across countries is equal to h55.16 for neonates. The UK had the lowest total costs of h42.86 (Ł37.43) per bag. The highest cost per bag was in Germany at h64.05 on average for neonates (h62.81 for a pharmacy compounded bag and h64.88 for a ward compounded bag). The cost of individualized admixtures increased with body weight. The average costs of PN for an infant aged o2 year were h84.52 per bag across the four countries (h60.26/Ł52.63 in the UK and h92.70 in Germany, h91.46 in the pharmacy and h93.53 at the ward). The total average cost for children between 2 and 18 years amounts to weighted h118.02 across all countries (h93.85 in Belgium, h121.35 in France, h124.54 in Germany and h79.56/Ł69.49 in UK). Nutrient costs represent with an average value of 63% the highest proportion of total costs for children in all four countries, while wages represent with 54% the highest proportion in neonates. Wage cost differs between pharmacy and ward compounding due to higher nurse workload (Table 3) .
Costs per patient
Results from the interviews showed that neonates receive PN for between 11 and 13 days. Total costs per patient for the different countries are presented in Table 3 . Total average treatment cost across all weight groups and all countries was equal to h688.41 for neonates. The average treatment cost across countries for infants o2 year was h492.54 (4 --9 days of PN), while the average treatment cost for children between 2 and 18 years amounted to h1085.56 (9 --10 days of PN).
Sensitivity analyses
The range of the sensitivity analyses for variation of 'discount rate' was derived from the interviews, and the discounts in the sensitivity analyses were assumed to be 10, 15 and 20% of the total nutrient costs (Figure 1 ). The total 'cross-country' costs per bag for neonates are hardly influenced by the discounts and were h53.76 with 10%, down to h52.37 with 20% discount. The results for the infants were h80.13 (10%) down to h75.74 (20%) and for the children h110.59 (10%) to h103.18 (20%), differing by h7 (10% discount) and h15 (20% discount) from undiscounted costs.
The range for the variation of 'time measurement' was derived from the interviews and represents the lowest and highest quoted minutes, namely 37 and 109 min (Figure 1 ). The total cross-country costs per bag for neonates are significantly influenced by personnel time. Lower personnel time reduces total costs per neonate bag down to h37.11; higher staff time leads to an increase of total costs per bag up to h59.97. Costs per bag for infants when varying personnel time range from h66.64 to h89.29, and for children between h98.40 and h123.26.
DISCUSSION
Cost analyses are increasingly important to support and justify medical procedures and reimbursement decisions. Often, cost analyses provide only partial results and do not encompass overall costs such as variable and fixed cost components, which need to incorporate personnel time and resource utilization. For instance, cost analyses that consider complex procedures such as PN Cost analysis of PN in Europecompounding cannot be restricted to the cost of nutrition solutions alone. 20 The aim of this study was to estimate the overall costs for in-hospital compounded PN bags in four countries by constructing a cost model. This approach includes not only the costs of the nutrition used but also the costs of personnel to prescribe and prepare PN, the costs for supplies used and the depreciation of equipment used.
The daily total average cost of one PN bag compounded in-hospital across all weight groups and across countries ranged between h55.16 for neonates up to h118.02 for children between 2 and 18 years. In the UK nutrients costs are the lowest but supply costs are comparatively high. Installations and device costs are lower in France, due to economies of scale of larger hospitals. Germany represents a high cost country in all cost components, except supplies. Cost differences between pharmacy and ward compounding are not significant in Belgium and Germany.
Our findings on compounding cost for pediatric PN are consistent with data from the literature. Only two studies calculated the PN costs for children. Gamsjäger et al.
2 evaluated for 50 pediatric patients requiring PN the nutrient costs of individualized admixtures of h81.78 ( þ /À16.33) per patient per day. They were higher than the corresponding theoretical costs of standard solutions, which accounted for h61.21 ( þ /À 6.55). Rey et al. 6 tried to find out whether the replacement of the patient-specific bags manufactured at Reims University Hospital by industrial admixtures, specifically Pediaven 1 (Fresenius KABI Laboratory France) standard solutions, leads to a cost reduction. Rey found that the cost of a compounded bag was h48 for an annual rate of 5800 bags, and concluded that while new standard bags seem more costly than 'patient-specific' preparations, using them came with advantages, in terms of ease of use and safety, that would allow the pharmacy team to devote themselves to other pharmaceutical tasks. Compounding costs from other PN cost studies are between h42.26/day and CHF148 (h92.44)/day. 3,20 --26 This study has the following limitations: total costs of hospital compounded bags are calculated using current official price lists, as it was not possible to obtain all necessary cost data from the recruited hospitals. Although we used manufacturer prices for Germany, we may still overestimate total costs. Therefore, in the sensitivity analyses, we consider discounts off the list price of nutrients. However, total costs are hardly influenced, and even with a discount of 20%, the highest change was seen in the infant group where costs decreased by up to h15. The salary information used in this study did not include any additional costs that employers bear such as national insurance and pensions, so the personnel costs are under-estimated.
Apart from the analysis of costs, individual preparation of PN gives the possibility of considerable errors in the calculation and the actual compounding, which can occur remarkably often even in a hospital pharmacy and 1.68 times more often if the production is done at the ward. 27, 28 Both compounding errors and contamination can have serious consequences for the patient. 2 Due to this reason, ward compounding is avoided in some countries (for example, France and the UK). In published literature, in the neonatal population, approximately 3.9% of medication errors are associated with harm. 29 Costs could actually be higher if there were infections or errors associated with compounding. Furthermore, these kinds of costs were not incorporated into the cost estimates.
This study estimated the costs of pediatric PN compounding by considering all elements involved in the process rather than just looking at the cost of the nutrients, as previous studies. This information should be helpful in determining the cost of administer PN and help health care providers compare the costs of preparation with alternative methods of delivering PN (such as ready-to-use formulations).
